Skip to main content

Recurrent UTI in Women

Recurrent urinary tract infection (rUTI) in women is defined as ≥2 UTIs in 6 months or ≥3 UTIs in 12 months (symptomatic episodes supported by pyuria and uropathogenic bacteria), affecting nearly 25% of women who experience an initial UTI.[1][2] The 2025 AUA / CUA / SUFU update emphasizes symptom-linked diagnosis, antimicrobial stewardship and informed choices among preventive options.[3][4] AUGS has sunset its 2018 best-practice statement in favor of the AUA / CUA / SUFU guideline.[41]

Part I: Epidemiology​

Over 50% of adult women experience at least one UTI in their lifetime.[5][1] In a study of college-aged women with a single UTI, 19–27% had a recurrence within six months.[1] Arnold et al. estimate that 30–44% of women have a second UTI within six months of an initial infection.[2]

Microbiology. Escherichia coli causes approximately 75% of recurrent UTIs. Other common organisms include Enterococcus faecalis, Proteus mirabilis, Klebsiella species, and Staphylococcus saprophyticus, particularly in patients with risk factors for complicated UTI.[5]

Part II: Pathophysiology — evolving understanding​

A. Traditional model — fecal-perineal-urethral ascent​

The classic model holds that uropathogenic bacteria from the gastrointestinal tract colonize the periurethral area, ascend the urethra, and cause cystitis. This model explains the association with sexual intercourse, spermicide use, and anatomic factors.[8][4]

B. Intracellular bacterial communities (IBCs) and quiescent intracellular reservoirs (QIRs)​

Experimental models show that UPEC can invade urothelial cells and form intracellular bacterial communities. The reservoir and reactivation sequence below is supported primarily by animal and organoid studies:[9][10][11]

  1. IBCs. UPEC binds to and invades superficial umbrella cells via type 1 pili, then replicates intracellularly to form biofilm-like communities. IBCs are transient and occur primarily during acute infection.[9]
  2. QIRs. After IBC dispersal, bacteria penetrate into deeper, immature urothelial layers where they enter a quiescent, non-replicating state. These QIRs are protected from antibiotics and immune surveillance.[9][12][11]
  3. Reactivation. As immature host cells differentiate and migrate toward the bladder lumen, dormant bacteria can reactivate and seed recurrent infection, potentially weeks to months after the initial episode.[12][11]

Rosen et al. (2007) found evidence consistent with IBC formation in humans. IBCs were found in 18% (14/80) of urine specimens from women with acute cystitis, and filamentous bacteria (a hallmark of IBC dispersal) were found in 41%.[10] Approximately 35% of clinical UPEC isolates demonstrate quorum-dependent quiescence in vitro.[13]

C. The urinary microbiome paradigm​

Updated models recognize that the bladder harbors a complex microbiome, and interactions between the urinary and vaginal environments and immune mechanisms at the bladder mucosal surface influence infection susceptibility. Postmenopausal women experience microbiome shifts (loss of protective Lactobacillus species) that increase vulnerability to recurrent infections.[4]

An early direct-sampling study supports the presence of bladder bacteria missed by routine culture. In women without known UTI, 16S rRNA gene sequencing detected bacteria not identified by standard clinical culture in voided urine, transurethral-catheter urine and suprapubic aspirates, regardless of urinary symptoms. Paired catheter and suprapubic samples had similar communities, whereas voided urine mixed urinary and genital-tract bacteria. The study did not establish whether these bacteria were viable or clinically relevant.[47]

Part III: Risk factors​

PopulationRisk factors
PremenopausalSexual intercourse ≥3× / week, spermicide use, new / multiple sex partners, UTI before age 15, history of UTI in first-degree female relative
PostmenopausalVaginal atrophy / hypoestrogenism, urinary incontinence, cystocele, elevated postvoid residual, prior UTI history
GeneticBlood-group antigen non-secretor phenotype, P1 phenotype, lower CXCR1 (IL-8 receptor) expression, family history of UTI in first-degree female relatives
Diabetes mellitusHigher prevalence of asymptomatic bacteriuria, UTI and rUTI; relative risk of rUTI about 1.5 versus women without diabetes (recurrence defined by antibiotic prescriptions in the source studies). Diabetes-specific prevention and treatment trials are lacking[40]
Not establishedPrecoital / postcoital voiding patterns, wiping patterns, specific beverage types, tampon use, douching, hot tub use, type of underwear, BMI
[1][2][3]

A population-based case-control study of 1,261 women 18-49 years old quantified the family-history association: compared with 430 controls with no UTI history, women with a UTI history in one first-degree female relative had an odds ratio of 3.1 (95% CI 2.1-4.7) for recurrent cystitis, and those with two or more affected relatives had an odds ratio of 5.0 (95% CI 3.1-8.1); risk increased similarly with pyelonephritis.[44]

Part IV: Diagnosis​

The 2025 AUA / CUA / SUFU guideline update emphasizes several diagnostic principles:[3][1][14]

Urine testing. Obtain urinalysis and culture with susceptibility testing during each symptomatic acute cystitis episode, before treatment when feasible. Document symptoms together with pyuria and uropathogenic bacteria. Interpret colony count in the clinical and collection context, and repeat a contaminated specimen.[3] The historical 10⁵ CFU/mL midstream threshold is insensitive in symptomatic women. In selected women with acute cystitis symptoms and pyuria, ≥10² CFU/mL of a single uropathogen, particularly E. coli, may support infection; interpret low counts by organism and collection method, and use a catheterized specimen when contamination is suspected.[3] On microscopy, about five bacteria per high-power field suggests a culture count near 100,000 CFU/mL.[48] This is not a diagnostic cutoff for symptomatic cystitis.[3]

Urinalysis. The 2025 update highlights the value of a negative urinalysis to lower the probability of acute cystitis in the index population. A negative urinalysis (negative nitrite and <5 WBC/hpf) helps exclude acute cystitis, whereas a positive one adds little diagnostic accuracy.[3]

Pelvic examination and emptying. Perform a pelvic examination in every woman with rUTI to document prolapse and look for urethral or periurethral pathology (urethral diverticulum, Skene gland cyst), vaginitis or vulvar dermatitis, genitourinary syndrome of menopause and pelvic-floor tenderness . Assess emptying with a postvoid residual (PVR). AUA 2025 states that this can be considered for all patients and should be done when incomplete emptying is suspected, for example with significant anterior vaginal wall prolapse, neurologic disease, diabetes or a sensation of incomplete emptying. The AUGS 2025 consensus advises pelvic examination and PVR in all women with ASB or rUTI, because an elevated PVR is a correctable risk factor and examination identifies conditions that mimic UTI (vulvar dermatitis, myofascial pelvic pain, atrophic vaginitis).[3][38] Vulvovaginal candidiasis is a mimic with its own cues: prominent vulvar pruritus, irritation, or soreness with vulvar inflammation, sometimes with little discharge, and a vaginal pH typically 4.0-4.5 (a higher pH favors bacterial vaginosis or trichomoniasis instead).[45] A saline wet mount with KOH can support the diagnosis, but microscopy can be negative in a confirmed case, and Candida colonization without symptoms is common.[45]

Asymptomatic bacteriuria and baseline LUTS. Omit surveillance urine cultures in asymptomatic women with rUTI and do not treat ASB . Pregnancy and urologic procedures that breach the mucosa are separate indications. In a follow-up analysis of 550 women with rUTI who completed follow-up (out of 673 originally enrolled in a randomized trial), those treated for ASB had more antibiotic-resistant E. coli and more recurrences (204/293 [69.6%] vs 97/257 [37.7%] over a mean 38.8 months).[3][38][39]

  • Chronic LUTS or OAB. Evaluate an acute change in symptoms with urinalysis and culture. Antibiotics may be indicated when pyuria and bacteriuria accompany the change. If symptoms do not improve, evidence does not support rescreening for bacteriuria or retreatment; consider mimics such as pelvic-floor myofascial pain and IC/BPS (AUGS 2025 Q14).[38] A small multicenter phase IIb trial in women with urodynamically proven, treatment-refractory detrusor overactivity randomized 36 women (2:1) to 6 weeks of rotating antibiotics or placebo, added to an anticholinergic for 6 months; 33 completed the trial.[46] The antibiotic group had greater reduction in 24-hour pad-test leakage (75 g versus 35 g) and a higher urge-incontinence cure rate (48% versus 17%) at 6 months, and fewer patients needed antibiotics for disabling cystitis symptoms outside the protocol (16.7% versus 41.6% of placebo).[46]
  • Persistent bacteriuria after treatment. Avoid repeated courses aimed at urinary sterilization. If symptoms have resolved, further treatment is not warranted. Retreatment can be considered for residual symptoms with a positive culture; after two culture-directed courses without resolution of bacteriuria and UTI symptoms, look for another symptomatic cause or source (AUGS 2025 Q18).[38]

Distinguishing relapse versus reinfection:[5]

  • Reinfection. Commonly used for a different organism or a later recurrence after apparent resolution.
  • Relapse or persistence. Same organism within 2 weeks; suggests occult source (calculi, diverticula, foreign body) requiring further evaluation.

Part V: Role of imaging and cystoscopy​

ACR 2026 distinguishes uncomplicated, complicated and pregnant populations; AUA uncomplicated-rUTI guidance supports selective investigation:[3][5][15][16]

Uncomplicated rUTI (no risk factors). Imaging is usually not appropriate. AUA 2025 advises against routine cystoscopy and upper tract imaging in the index patient because the yield of anatomic abnormalities is low.[3] Poor response to treatment or rapid recurrence with the same organism may warrant cystoscopy and upper tract imaging; the guideline recommends upper tract imaging for a history of hematuria, suspected pyelonephritis, or renal calculi.[3] Gross hematuria with a positive urine culture and no urothelial malignancy risk factors does not itself require cystoscopy; cystoscopy should be performed when such risk factors are present, and gross hematuria without documented infection warrants bladder cancer evaluation.[3][5][16] The EAU 2026 guideline defines recurrent cystitis as at least three episodes in a year or two in six months, recommends confirming the diagnosis by urine culture , and gives a weak recommendation against an extensive routine workup such as cystoscopy or full-abdominal ultrasound in women younger than 40 years with no risk factors.[37] It advises evaluation without delay in atypical cases, for example suspected calculi, outflow obstruction, interstitial cystitis or urothelial cancer.[37]

Complicated rUTI or red flags. Imaging should be considered when:[5][15]

  • Rapid recurrence within 2 weeks (relapse / persistence).
  • Nonresponse to conventional therapy.
  • Hematuria persisting after infection resolution.
  • Known risk factors (calculi, prior surgery, anatomic abnormalities, pneumaturia, fecaluria).
  • Select imaging for the suspected cause: ultrasound is a reasonable screen, and CT urography provides comprehensive assessment when appropriate. When imaging is indicated for suspected complications in pregnancy, use ultrasound first and noncontrast MRI selectively; avoid treating all complicated presentations as a universal CTU/MRU indication.[15]

Flowmetry and postvoid residual (PVR). PVR assessment is reasonable at the initial evaluation (AUA 2025; AUGS 2025 Q19), and flowmetry is useful when impaired emptying is suspected.[3][38] In a retrospective two-hospital referral cohort of 593 women, flowmetry or PVR was abnormal in 134, cystoscopy in 14 and ultrasound in 42; diagnostic testing changed treatment in 117, mostly because of flow/PVR findings.[16]

Part VI: Treatment of acute episodes​

Treatment of an acute rUTI episode follows the same principles as sporadic uncomplicated cystitis:[1][2][17]

First-line agents (per IDSA / AUA guidelines):

Choose nitrofurantoin, TMP-SMX or fosfomycin according to cultures, local resistance, allergy and renal function, using the shortest appropriate course, generally no longer than seven days .[3] Use the UTI treatment antibiotics hub for dosing; prevention and acute-treatment regimens are different.[3][17][18]

Part VII: Prevention — non-antibiotic strategies​

The 2025 AUA / CUA / SUFU update expands counselling on non-antibiotic preventive options alongside discussion of antibiotic benefits and harms.[3][4]

A. Vaginal estrogen (peri- and postmenopausal women)​

The AUA / CUA / SUFU 2025 guideline recommends vaginal estrogen for peri- and postmenopausal women with rUTI when it is not contraindicated .[3][14]

  • Raz and Stamm (1993). Landmark NEJM placebo-controlled trial of intravaginal estriol; cumulative protection from UTI markedly higher in the estrogen group than placebo, establishing topical estrogen as a foundational rUTI-prevention strategy in postmenopausal women.[22]
  • Meta-analysis of 5 RCTs (1,936 patients). Vaginal estrogen reduced rUTIs by 58% (RR 0.42; 95% CI 0.30–0.59) compared with placebo. Oral estrogen showed no benefit (RR 1.11; 95% CI 0.92–1.35).[20]
  • Tan-Kim et al. (2023). In a retrospective cohort of 5,638 women prescribed vaginal estrogen for rUTI, UTI frequency decreased by 51.9% (from 3.9 to 1.8 episodes / year; p<0.001).[21]

Formulations. Choose cream, low-dose ring or insert according to preference, feasibility and product-specific safety. Use the vaginal-estrogen prescribing hub for loading and maintenance regimens.[23]

Application update (TAPER, July 2026). A small randomized trial supports discussing periurethral cream when intravaginal applicator use is difficult, with a wide noninferiority margin. See the estrogen hub for regimens, results, and limitations.[34]

B. Methenamine hippurate​

AUA 2025 permits methenamine hippurate prophylaxis for women with rUTI . It is a urinary antiseptic that can reduce reliance on daily antibiotics. Do not routinely add vitamin C: urinary acidifiers have not been shown to lower urinary pH significantly or to enhance methenamine in RCTs, so AUA advises against combining them. For the regimen, contraindications, and pH/label distinction, use the methenamine prescribing hub.[3][24][27]

  • ALTAR trial (Harding et al., 2022; 240 randomized, 205 in the modified intention-to-treat primary analysis). Multicenter RCT demonstrated methenamine hippurate non-inferior to daily low-dose antibiotics for prevention of symptomatic, antibiotic-treated UTIs during 12 months (1.38 vs. 0.89 episodes / person-year; absolute difference 0.49, within the predefined non-inferiority margin of 1 UTI / person-year).[25] Among participants whose optional perineal swabs yielded E. coli, resistance to at least one antibiotic at the 6- or 12-month visit was found in 46/64 antibiotic versus 39/70 methenamine participants (72% vs. 56%; p = 0.05); at 18 months, six months after treatment ended, multidrug resistance was found in 9/45 methenamine versus 2/39 antibiotic participants (20% vs. 5%; p = 0.06).[24] Both analyses were exploratory.[24]
  • ImpresU trial (Heltveit-Olsen et al., 2025; 289 women recruited, 281 analyzed; age ≥70 years). The modified intention-to-treat analysis estimated 25% fewer antibiotic treatments for UTI during 6 months with methenamine than placebo (IRR 0.75; 95% CI 0.57–1.0; p = 0.049); the complete-case analysis of 271 women gave IRR 0.77 (95% CI 0.58–1.0; p = 0.078). After discontinuation, the methenamine group had a higher incidence of antibiotic-treated episodes during the six-month follow-up (IRR 1.7; 95% CI 1.3–2.3).[26]
  • Emerging concern. Hodgkinson et al. (2026) identified growth above the study-defined formaldehyde threshold in 11/191 ALTAR-derived E. coli isolates (5.8%), with frmR variants or plasmid mechanisms. The genomic and laboratory findings support possible resistance evolution.[27]

C. Cranberry products​

Across mixed populations and 14 interventions, a 50-RCT network meta-analysis (10,495 participants) estimated lower UTI incidence with cranberry than placebo (RR 0.72; 95% CI 0.60–0.87).[28] The WikiGuidelines consensus (2024) gives a clear recommendation for cranberry products containing 36 mg proanthocyanidins in women with rUTI, children, and people susceptible to UTIs after interventions.[29] Cochrane 2023 found fewer symptomatic, culture-verified UTIs with cranberry than with placebo or control in women with rUTI (8 trials, 1,555 participants; RR 0.74, 95% CI 0.55–0.99), but direct comparisons with antibiotics remain too limited to establish superiority or equivalence.[35] Benefit was not shown in institutionalized older adults, pregnancy or neuromuscular bladder dysfunction with incomplete emptying. AUA 2025 advises clinicians to offer cranberry as an option . Optimal product and dose remain uncertain.[3][35]

D. D-mannose​

Guidelines. AUA/CUA/SUFU 2025 advises counseling that D-mannose alone may not prevent recurrence ; EAU 2026 weakly recommends its use while describing efficacy evidence as weak and contradictory.[3][37] A network meta-analysis across mixed populations favored D-mannose, whereas MERIT provides larger blinded evidence in women with rUTI.[28][6]

In MERIT, a double-blind primary-care RCT of 598 women with rUTI, D-mannose 2 g daily did not significantly reduce medically attended, clinically suspected UTI over 6 months versus placebo (150/294 [51.0%] versus 161/289 [55.7%]; risk difference −5 percentage points, 95% CI −13 to 3); the authors concluded that D-mannose should not be recommended for prophylaxis in this population.[6]

E. Probiotics​

Across mixed study populations, pooled probiotic interventions had lower UTI incidence than placebo (RR 0.69; 95% CI 0.50–0.94) in the network meta-analysis.[28] Older consensus discussions considered probiotics.[23] AUA 2025 cannot recommend Lactobacillus prophylaxis because of limited comparative evidence and unavailable trial strains.[3] EAU 2026 weakly advises local or oral probiotics containing strains with evidence of vaginal-flora regeneration to prevent cystitis.[37]

F. Behavioral modifications​

  • Discuss increased water intake in premenopausal women who drink little: in an open-label RCT of 140 women (usual intake below 1.5 L/day), an extra 1.5 L of water daily reduced cystitis episodes (mean 1.7 vs 3.2 per year).[19] Individualize for fluid restrictions.[3][19]
  • Avoidance of spermicidal contraceptives.[5]

G. Immunoprophylaxis​

  • MV140. In a placebo-controlled trial, 240 women with at least five uncomplicated cystitis episodes in the prior year were randomized to three months of MV140, six months of MV140, or placebo; among 215 in the protocol-defined primary analysis, 39/70 (56%), 40/69 (58%), and 19/76 (25%), respectively, remained free of symptomatic, culture-positive UTI during the nine-month efficacy period after the first three months.[36]
  • EAU 2026 recommends immunomodulatory prophylaxis only within a well-regulated clinical trial , reflecting limited and heterogeneous evidence.[37] OM-89 and MV140 are different products.

Part VIII: Prevention — antibiotic prophylaxis​

AUA 2025 permits antibiotic prophylaxis after discussing benefits, harms and alternatives .[3] EAU 2026 recommends continuous or postcoital prophylaxis when non-antimicrobial interventions have failed , and chooses between them by whether episodes follow intercourse and by patient preference; distinguish these guideline frameworks.[3][37]

Continuous or intercourse-associated prophylaxis​

Discuss expected benefits, drug toxicity, resistance, previous cultures and preferences. Continuous prophylaxis may suit infections without a consistent trigger; postcoital prophylaxis can limit exposure when recurrences track intercourse. The guideline does not require failure of every non-antibiotic option before this discussion.[3][17][2] The UK NICE guideline (NG112, updated December 2024) is more stepwise: hygiene advice, vaginal estrogen, single-dose prophylaxis, methenamine, then daily antibiotics, with review of daily prophylaxis at least every 6 months.[42]

Use the UTI suppressive/prophylactic antibiotics hub for agent selection, regimens, monitoring and contraindications. Fluoroquinolones are not routine prophylaxis: AUA 2025 notes that tendon rupture (boxed warning), QT prolongation, seizures and C. difficile infection generally outweigh their benefit for localized UTI.[3]

Trials generally evaluated 6–12 months; periodically reassess ongoing need. Recurrence may return after stopping. Treat an active episode, but do not require a routine negative test-of-cure culture in an asymptomatic patient before prevention.[3][29]

Part IX: Special populations​

Postmenopausal women. Include vaginal estrogen when appropriate and discuss the other preventive options according to eligibility and preference:[3][14][21]

  1. Vaginal estrogen (AUA 2025 Moderate Recommendation, Grade B, for peri- and postmenopausal women with rUTI when not contraindicated).[3]
  2. Non-antibiotic prevention (prescription methenamine or cranberry products, according to eligibility).
  3. Antibiotic prophylaxis when its benefits, risks and patient preferences support it.

Women with anatomic or functional abnormalities. Cystocele, elevated PVR, urethral diverticula, or mesh erosion require targeted evaluation and treatment of the underlying condition.[5][31]

Women with diabetes. The AUGS diabetes consensus (2026) found no evidence that lower-tract UTI management should differ from women without diabetes, and noted limited prospective diabetes-specific evidence for UTI prevention and treatment.[40]

  1. Assess emptying with a PVR; diabetes is one of the AUA 2025 triggers.[3]
  2. In women with diabetes, ASB is common, and its prevalence is associated with higher HbA1c and SGLT2-inhibitor use. The AUGS consensus states that there are no data to support treating ASB in these women and that progression to pyelonephritis or urosepsis is low; an observational cohort found no adjusted association between ASB and decline in creatinine clearance over approximately 6 years.[38]
  3. Prevention follows the general pathway: vaginal estrogen and methenamine hippurate can prevent UTI in women with and without diabetes (mostly type 2 in the studies), and cranberry data in diabetes are limited.[40]
  4. Worsening glycemic control is thought to raise UTI risk. SGLT2 inhibitors may confer a slightly higher UTI risk than other oral agents (evidence conflicting), and GLP-1 receptor agonists do not appear to change it. Limited data link HbA1c of 8% or higher to postoperative UTI after pelvic-floor surgery. The statement sets no glycemic target and does not advise stopping SGLT2 inhibitors.[40]

Antibiotic-resistant infections. For complex, refractory infections, Sze et al. advise consultation with infectious-disease and allergy specialists as expert opinion.[30] Selected intravesical therapies may limit systemic drug exposure, but evidence is heterogeneous and resistance can still emerge.[30]

Part X: Emerging therapies​

A. Bacteriophage therapy​

The 2024 ELIMINATE part 1 report described 39 women in an uncontrolled, open-label phase II dose-finding study of LBP-EC01 plus TMP-SMX. No serious adverse events occurred, but higher intravenous doses produced tolerability signals and the protocol changed. All 16 evaluable participants had symptom resolution and reduced urinary E. coli counts by day 10.[7]

Joshi et al. (2026) showed that lytic phage ΦHP3 reduced UPEC adhesion and invasion of vaginal and bladder epithelial cells in vitro, and daily intravaginal phage administration significantly reduced vaginal UPEC burden in humanized-microbiota mice.[32]

B. UTI vaccines​

See immunoprophylaxis for the MV140 randomized trial and current EAU restriction. A network estimate combining different vaccine preparations (RR 0.65, 95% CI 0.52–0.82) does not establish class-wide effectiveness or routine availability.[28][30][37]

C. Fecal microbiota transplantation (FMT)​

Initial findings suggest FMT may interrupt the rUTI cycle by restoring a healthy gut microbiome and reducing intestinal colonization with uropathogenic organisms, though clinical data remain preliminary.[33]

D. Intravesical therapies​

Intravesical glycosaminoglycan (GAG) layer replenishment (hyaluronic acid ± chondroitin sulfate) aims to restore the protective bladder lining. Some evidence supports reduced UTI recurrence, though data quality is limited.[30]

Part XI: Management algorithm​

Based on the 2025 AUA / CUA / SUFU update and multisociety consensus:[3][1][23]

  1. Confirm the diagnosis. Relate recurrent acute symptoms to pyuria and uropathogenic bacteria; obtain urine testing for each acute episode and rule out other causes of LUTS. Perform a pelvic examination (prolapse, urethral or periurethral lesions, GSM, pelvic-floor tenderness) , and measure a PVR when incomplete emptying is suspected.[3][1] Outside pregnancy and planned urologic procedures that breach the mucosa, do not screen for or treat asymptomatic bacteriuria.[3][37][38]
  2. Treat the acute episode. Short-course antibiotics (nitrofurantoin, TMP-SMX, or fosfomycin).
  3. Identify and modify risk factors. Spermicide avoidance, behavioral modifications, adequate hydration.
  4. Discuss preventive choices:
    • Perimenopausal and postmenopausal. Vaginal estrogen when appropriate[3] ± methenamine hippurate ± cranberry.
    • Premenopausal. Behavioral modifications, cranberry, consider methenamine hippurate.
  5. Antibiotic strategies when selected after counselling:
    • Intercourse-related: postcoital single-dose prophylaxis.
    • Non-intercourse-related: continuous prophylaxis with planned review.
    • Selected reliable nonpregnant patients with localized cystitis symptoms may start a pre-agreed treatment course while a culture is pending ; fever or flank pain prompts assessment for systemic UTI.[3][37] Use agents chosen from prior cultures and the local antibiogram, still obtain a culture for symptomatic recurrences when feasible, and record how often self-start is used.
  6. Further evaluation for atypical presentations, poor response, or rapid recurrence:
    • Flowmetry (and repeat PVR) when emptying dysfunction is suspected or treatment fails.
    • Select imaging for the suspected cause: renal and bladder ultrasound can be an initial screen; CT urography or MR urography may be used when detailed evaluation is indicated. In pregnancy, use ultrasound first and noncontrast MRI selectively.[15]
    • Consider cystoscopy for gross hematuria without documented infection or with urothelial-malignancy risk factors, hematuria persisting after infection resolution, suspected structural pathology, poor treatment response, or rapid recurrence, particularly with the same organism.[3]
    • Multidisciplinary referral (urology, infectious disease, urogynecology).

Part XII: Key paradigm shifts (2025 update)​

The 2025 AUA / CUA / SUFU guideline update and contemporary reviews highlight several important shifts:[3][4]

  • Avoid treating microbial detection alone. Protect against unnecessary antibiotics while treating symptomatic infection. A 2024 proposal frames this as a five-category "continuum of UTI" that replaces the traditional three discrete categories (UTI, asymptomatic bacteriuria, no UTI) with additional categories for bacteriuria of unclear significance (a positive culture with one nonspecific clinical criterion or inability to report symptoms) and for lower-urinary-tract or other urologic symptoms without confirmed bacteriuria.[43]
  • More preventive choices. Vaginal estrogen, methenamine and cranberry can reduce antibiotic exposure.
  • From microbial detection to clinical judgment. A negative urinalysis lowers the likelihood of acute cystitis in the index population.
  • From routine cystoscopy to selective evaluation. Cystoscopy and imaging are reserved for complicated presentations, not routine rUTI.
  • Antimicrobial stewardship. Recognition that repetitive antibiotic use causes collateral damage (rising resistance, microbiome disruption, and adverse effects) drives the search for alternatives.

Selected evidence​

ALTAR · 2022[24]; MERIT · 2024[6].

Recurrent UTI in women — key study comparisons
Study and populationComparison and resultsUse and limitations
ALTAR · 2022

Adult women with recurrent UTI for whom prophylaxis was indicated; excluded neurogenic dysfunction and correctable urinary abnormalities.

Randomized n=240

Source and methods: ALTAR · 2022
Source
Harding C et al. Alternative to Prophylactic Antibiotics for the Treatment of Recurrent Urinary Tract Infections in Women: Multicentre, Open Label, Randomised, Non-inferiority Trial (2022). DOI: 10.1136/bmj-2021-0068229
Design
Open-label randomized noninferiority trial
Denominators
120 randomized per group; modified intention-to-treat primary analysis required ≥6 months follow-up.
Follow-up
12 months treatment plus 6 months off treatment
Methenamine hippurate vs daily low-dose antibiotic prophylaxis

Symptomatic antibiotic-treated UTI episodes per person-year · 12 months treatment

1.38 with methenamine vs 0.89 with antibiotics.

Absolute difference 0.49 episodes/year; 90% CI 0.15–0.84; prespecified noninferiority margin 1 episode/year.

An antibiotic-sparing option after shared decisions; check the drug hub for contraindications and dosing.

  • Open label.
MERIT · 2024

Adult women with recurrent UTI at 99 UK primary-care centres.

Randomized n=598

Source and methods: MERIT · 2024
Source
Hayward G et al. d-Mannose for Prevention of Recurrent Urinary Tract Infection Among Women: A Randomized Clinical Trial (2024). DOI: 10.1001/jamainternmed.2024.0264
Design
Double-blind randomized placebo-controlled trial
Denominators
303 assigned d-mannose, 295 placebo; primary outcome available in 294 and 289.
Follow-up
6 months
Daily d-mannose vs placebo

At least one medically attended clinically suspected UTI · 6 months

150/294 (51.0%) vs 161/289 (55.7%).

Risk difference −5 percentage points; 95% CI −13 to 3; P=.26.

Do not routinely recommend d-mannose for prevention in this population.

  • Primary outcome was clinically suspected, not necessarily culture-confirmed, UTI.

See Also​

Podcasts​

Recurrent UTI: Diagnostics & Management Strategies
BackTable Urology, Ep. 324 (2026) · Glenn Werneburg, Anjali Kapur
backtable.com
SUFU 21 Fact or Fiction: Lactobacillus, Increased Water Intake, D-Mannose and Methenamine Minimize Risk of Recurrent UTI
SUFU Podcast (2021)
podcasts.apple.com

References​

1. Advani SD, Thaden JT, Perez R, et al. "State-of-the-art review: recurrent uncomplicated urinary tract infections in women." Clin Infect Dis. 2025;80(3):e31–e42. doi:10.1093/cid/ciae653

2. Arnold JJ, Hehn LE, Klein DA. "Common questions about recurrent urinary tract infections in women." Am Fam Physician. 2016;93(7):560–569.

3. Ackerman AL, Bradley M, D'Anci KE, et al. "Updates to recurrent uncomplicated urinary tract infections in women: AUA / CUA / SUFU guideline (2025)." J Urol. 2026;215(1):3–12. doi:10.1097/JU.0000000000004723

4. Siddiqui NY, Bradley MS. "Updates in clinical management of recurrent urinary tract infections." Obstet Gynecol. 2025. doi:10.1097/AOG.0000000000006060

5. Venkatesan AM, Oto A, Allen BC, et al. "ACR Appropriateness Criteria® recurrent lower urinary tract infections in females." J Am Coll Radiol. 2020;17(11S):S487–S496. doi:10.1016/j.jacr.2020.09.003

6. Hayward G, Mort S, Hay AD, et al. "D-mannose for prevention of recurrent urinary tract infection among women: a randomized clinical trial." JAMA Intern Med. 2024;184(6):619–628. doi:10.1001/jamainternmed.2024.0264

7. Kim P, Sanchez AM, Penke TJR, et al. "Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial." Lancet Infect Dis. 2024;24(12):1319–1332. doi:10.1016/S1473-3099(24)00424-9

8. Hooton TM. "Uncomplicated urinary tract infection." N Engl J Med. 2012;366(11):1028–1037. doi:10.1056/NEJMcp1104429

9. Hannan TJ, Totsika M, Mansfield KJ, et al. "Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection." FEMS Microbiol Rev. 2012;36(3):616–648. doi:10.1111/j.1574-6976.2012.00339.x

10. Rosen DA, Hooton TM, Stamm WE, Humphrey PA, Hultgren SJ. "Detection of intracellular bacterial communities in human urinary tract infection." PLoS Med. 2007;4(12):e329. doi:10.1371/journal.pmed.0040329

11. Sharma K, Thacker VV, Dhar N, et al. "Early invasion of the bladder wall by solitary bacteria protects UPEC from antibiotics and neutrophil swarms in an organoid model." Cell Rep. 2021;36(3):109351. doi:10.1016/j.celrep.2021.109351

12. Blango MG, Ott EM, Erman A, Veranic P, Mulvey MA. "Forced resurgence and targeting of intracellular uropathogenic Escherichia coli reservoirs." PLoS One. 2014;9(3):e93327. doi:10.1371/journal.pone.0093327

13. DiBiasio EC, Ranson HJ, Johnson JR, et al. "Peptidoglycan sensing prevents quiescence and promotes quorum-independent colony growth of uropathogenic Escherichia coli." J Bacteriol. 2020;202(20):e00157-20. doi:10.1128/JB.00157-20

14. Anger JT, Bixler BR, Holmes RS, et al. "Updates to recurrent uncomplicated urinary tract infections in women: AUA / CUA / SUFU guideline." J Urol. 2022;208(3):536–541. doi:10.1097/JU.0000000000002860

15. Expert Panel on Urological Imaging, Ward RD, Allen BC, et al. "ACR Appropriateness Criteria® recurrent lower urinary tract infections in females: update 2026." J Am Coll Radiol. 2026. doi:10.1016/j.jacr.2026.03.006

16. Pat JJ, Steffens MG, Witte LPW, Marcelissen TAT, Blanker MH. "Comparison of the diagnostic yield of routine versus indicated flowmetry, ultrasound and cystoscopy in women with recurrent urinary tract infections." Int Urogynecol J. 2022;33(8):2283–2289. doi:10.1007/s00192-021-04871-2

17. Fihn SD. "Acute uncomplicated urinary tract infection in women." N Engl J Med. 2003;349(3):259–266. doi:10.1056/NEJMcp030027

18. Stamm WE, Hooton TM. "Management of urinary tract infections in adults." N Engl J Med. 1993;329(18):1328–1334. doi:10.1056/NEJM199310283291808

19. Hooton TM, Vecchio M, Iroz A, et al. "Effect of increased daily water intake in premenopausal women with recurrent urinary tract infections: a randomized clinical trial." JAMA Intern Med. 2018;178(11):1509–1515. doi:10.1001/jamainternmed.2018.4204

20. Chen YY, Su TH, Lau HH. "Estrogen for the prevention of recurrent urinary tract infections in postmenopausal women: a meta-analysis of randomized controlled trials." Int Urogynecol J. 2021;32(1):17–25. doi:10.1007/s00192-020-04397-z

21. Tan-Kim J, Shah NM, Do D, Menefee SA. "Efficacy of vaginal estrogen for recurrent urinary tract infection prevention in hypoestrogenic women." Am J Obstet Gynecol. 2023;229(2):143.e1–143.e9. doi:10.1016/j.ajog.2023.05.002

22. Raz R, Stamm WE. "A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections." N Engl J Med. 1993;329(11):753–756. doi:10.1056/NEJM199309093291102

23. Smith AL, Brown J, Wyman JF, et al. "Treatment and prevention of recurrent lower urinary tract infections in women: a rapid review with practice recommendations." J Urol. 2018;200(6):1174–1191. doi:10.1016/j.juro.2018.04.088

24. Harding C, Mossop H, Homer T, et al. "Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open-label, randomised, non-inferiority trial." BMJ. 2022;376:e068229. doi:10.1136/bmj-2021-0068229

25. Harding C, Chadwick T, Homer T, et al. "Methenamine hippurate compared with antibiotic prophylaxis to prevent recurrent urinary tract infections in women: the ALTAR non-inferiority RCT." Health Technol Assess. 2022;26(23):1–172. doi:10.3310/QOIZ6538

26. Heltveit-Olsen SR, Arnljots ES, Sundvall PD, et al. "Methenamine hippurate as prophylaxis for recurrent urinary tract infections in older women — a triple-blind, randomised, placebo-controlled, phase IV trial (ImpresU)." Clin Microbiol Infect. 2025. doi:10.1016/j.cmi.2025.07.006

27. Hodgkinson NC, Al-Rubaye T, Reed TCP, et al. "Implications for methenamine hippurate use in recurrent urinary tract infection management: formaldehyde resistance and altered urinary composition." PLoS Pathog. 2026;22(3):e1014081. doi:10.1371/journal.ppat.1014081

28. Han Z, Yi X, Li J, Liao D, Ai J. "Nonantibiotic prophylaxis for urinary tract infections: a network meta-analysis of randomized controlled trials." Infection. 2025;53(2):535–546. doi:10.1007/s15010-024-02357-z

29. Nelson Z, Aslan AT, Beahm NP, et al. "Guidelines for the prevention, diagnosis, and management of urinary tract infections in pediatrics and adults: a WikiGuidelines Group consensus statement." JAMA Netw Open. 2024;7(11):e2444495. doi:10.1001/jamanetworkopen.2024.44495

30. Sze C, Attia S, Zimmern P. "Effective risk-reduction strategies and pharmacological treatment for uncomplicated recurrent urinary tract infections." Expert Opin Pharmacother. 2025. doi:10.1080/14656566.2025.2584405

31. Nosseir SB, Lind LR, Winkler HA. "Recurrent uncomplicated urinary tract infections in women: a review." J Womens Health (Larchmt). 2012;21(3):347–354. doi:10.1089/jwh.2011.3056

32. Joshi B, Zulk JJ, Serchejian C, et al. "Bacteriophage-mediated reduction of uropathogenic E. coli from the urogenital epithelium." Infect Immun. 2026;94(4):e0054325. doi:10.1128/iai.00543-25

33. Zare M, Vehreschild MJGT, Wagenlehner F. "Management of uncomplicated recurrent urinary tract infections." BJU Int. 2022;129(6):668–678. doi:10.1111/bju.15630

34. Zuo SW, Mowers EE, Hem S, et al. "Vaginal Estrogen Application Techniques for Prevention of Urinary Tract Infection: A Randomized Trial." Obstet Gynecol. Published online July 27, 2026. doi:10.1097/AOG.0000000000006376

35. Williams G, Stothart CI, Hahn D, et al. "Cranberries for preventing urinary tract infections." Cochrane Database Syst Rev. 2023;11:CD001321. doi:10.1002/14651858.CD001321.pub7

36. Lorenzo-Gómez MF, Foley S, Nickel JC, et al. "Sublingual MV140 for Prevention of Recurrent Urinary Tract Infections." NEJM Evid. 2022;1(4):EVIDoa2100018. doi:10.1056/EVIDoa2100018

37. European Association of Urology. Guidelines on Urological Infections. 2026. Recurrent cystitis recommendations.

38. Siddiqui NY, Ackerman AL, Advani SD, et al. "Management of Asymptomatic Bacteriuria in Adult Female Populations." Urogynecology (Phila). 2025;31(9):827–845. doi:10.1097/SPV.0000000000001731

39. Cai T, Nesi G, Mazzoli S, et al. "Asymptomatic bacteriuria treatment is associated with a higher prevalence of antibiotic resistant strains in women with urinary tract infections." Clin Infect Dis. 2015;61(11):1655–1661. doi:10.1093/cid/civ696

40. Dueñas-Garcia OF, Chung DE, Geynisman-Tan J, et al. "Diabetes Mellitus and Recurrent Urinary Tract Infections." Urogynecology (Phila). 2026;32(5):477–485. doi:10.1097/SPV.0000000000001823

41. Lowder JL, Brubaker L. "Sunsetting the 2018 AUGS Best-Practice Statement on Recurrent Urinary Tract Infection." Urogynecology (Phila). 2026;32(7):773–774. doi:10.1097/SPV.0000000000001849

42. NICE. Urinary tract infection (recurrent): antimicrobial prescribing (NG112). Published October 31, 2018; last updated December 12, 2024. Guideline

43. Advani SD, Turner NA, North R, et al. "Proposing the 'Continuum of UTI' for a Nuanced Approach to Diagnosis and Management of Urinary Tract Infections." J Urol. 2024;211(5):690-698. doi:10.1097/JU.0000000000003874

44. Scholes D, Hawn TR, Roberts PL, et al. "Family History and Risk of Recurrent Cystitis and Pyelonephritis in Women." J Urol. 2010;184(2):564-569. doi:10.1016/j.juro.2010.03.139

45. Sobel JD. Vaginitis. In: Cardozo L, Staskin D, eds. Textbook of Female Urology and Urogynecology. Vol 1: Clinical Perspectives. 5th ed. CRC Press; 2023:628–637.

46. Chen Z, Moore KH, Mansfield KJ, et al. "Effect of Antibiotics on Urine Leakage in Women with Refractory Detrusor Overactivity: A Phase IIb Randomized Trial." Neurourol Urodyn. 2021;40(1):158-167. doi:10.1002/nau.24525

47. Wolfe AJ, Toh E, Shibata N, Rong R, Kenton K, FitzGerald M, et al. "Evidence of uncultivated bacteria in the adult female bladder." J Clin Microbiol. 2012;50(4):1376-1383. doi:10.1128/JCM.05852-11

48. Hitzeman N, Greer D, Carpio E. "Office-Based Urinalysis: A Comprehensive Review." Am Fam Physician. 2022;106(1):27–35B. PMID:35839369